Alector (ALEC) Non-Current Assets (2018 - 2026)
Alector's (ALEC) quarterly Non-Current Assets came in at $22.8 million in Q2 2026, down 38.87% year-over-year from $37.2 million in Q2 2025, and down 8.31% quarter-over-quarter from $24.8 million in Q1 2026.
Analysis
Alector (ALEC) Non-Current Assets (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Non-Current Assets for 9 consecutive years, with $22.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 38.87% year-over-year to $22.8 million in Q2 2026; TTM through Jun 2026 was $109.3 million, a 35.35% decrease from a year earlier, with the FY2025 full-year figure at $26.8 million, down 38.41% from the prior year.
- Non-Current Assets was $22.8 million for Q2 2026 at Alector, down from $24.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $63.5 million in Q1 2022 and troughed at $22.8 million in Q2 2026.
- A 5-year average of $48.4 million and a median of $52.6 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets declined 1.87% in 2023 and sank 40.38% in 2026, its largest moves.
- Over 5 years, Non-Current Assets stood at $61.2 million in 2022, then declined by 8.48% to $56.0 million in 2023, then decreased by 22.37% to $43.5 million in 2024, then sank by 38.41% to $26.8 million in 2025, then slipped by 15.0% to $22.8 million in 2026.
- The last three Non-Current Assets figures came in at $22.8 million (Q2 2026), $24.8 million (Q1 2026), and $26.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | 22.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.77 Mn |
| Mar 31, 2026 | 24.83 Mn |
| Dec 31, 2025 | 26.79 Mn |
| Sep 30, 2025 | 34.90 Mn |
| Jun 30, 2025 | 37.24 Mn |
| Mar 31, 2025 | 41.65 Mn |
| Dec 31, 2024 | 43.49 Mn |
| Sep 30, 2024 | 46.66 Mn |
| Jun 30, 2024 | 51.03 Mn |
| Mar 31, 2024 | 54.10 Mn |
| Dec 31, 2023 | 56.02 Mn |
| Sep 30, 2023 | 59.25 Mn |
| Jun 30, 2023 | 60.75 Mn |
| Mar 31, 2023 | 62.34 Mn |
| Dec 31, 2022 | 61.21 Mn |
| Sep 30, 2022 | 62.08 Mn |
| Jun 30, 2022 | 62.65 Mn |
| Mar 31, 2022 | 63.53 Mn |
| Dec 31, 2021 | 64.95 Mn |
| Sep 30, 2021 | 66.21 Mn |